Drug
Rv3391a
Rv3391a: highest development phase Phase 3, developed by Pierre Fabre. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Pierre Fabre
Trials
| Drug | Phase | Indication |
|---|---|---|
| RV3391A NCT00709579 | Phase 3 | Cortico Atrophy |
Latest
No recent events.
Follow Rv3391a on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.